Cullen/Frost Bankers’s Ascendis Pharma A/S ASND Stock Holding History

Cullen/Frost Bankers’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12K	Sell	45 -2	-4%	-$467	﹤0.01%	1138
2026 Q1	$10.8K	Hold	47	–	–	﹤0.01%	1097
2025 Q4	$10K	Buy	47 +2	+4%	+$413	﹤0.01%	1115
2025 Q3	$8.95K	Hold	45	–	–	﹤0.01%	1095
2025 Q2	$7.77K	Hold	45	–	–	﹤0.01%	1059
2025 Q1	$7.01K	Buy	45 +4	+10%	+$571	﹤0.01%	1001
2024 Q4	$5.64K	Hold	41	–	–	﹤0.01%	979
2024 Q3	$6.12K	Buy	41 +38	+1,267%	+$5.13K	﹤0.01%	959
2024 Q2	$409	Buy	+3	New	+$408	﹤0.01%	1213
2024 Q1	–	Sell	-100	Closed	-$12.6K	–	1001
2023 Q4	$12.6K	Hold	100	–	–	﹤0.01%	789
2023 Q3	$9.36K	Buy	+100	New	+$9.36K	﹤0.01%	932

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Cullen/Frost Bankers's ASND Position: Q2 2026 in Review

Cullen/Frost Bankers reduced its Ascendis Pharma A/S (ASND) stake by 4.3% in Q2 2026, selling an estimated $467 and leaving 45 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #1138.

Cullen/Frost Bankers first reported a position in ASND in Q3 2023 and has held it in 11 quarters since. The position peaked at $12.6K in Q4 2023. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Cullen/Frost Bankers held 45 shares of Ascendis Pharma A/S worth $12K as of Q2 2026.
Cullen/Frost Bankers sold 2 Ascendis Pharma A/S shares in Q2 2026, an estimated $467.
Ascendis Pharma A/S made up ﹤0.01% of Cullen/Frost Bankers's portfolio in Q2 2026, its #1138 holding.
Cullen/Frost Bankers first reported a position in Ascendis Pharma A/S in Q3 2023 and has held it in 11 quarters since.
Cullen/Frost Bankers's Ascendis Pharma A/S position peaked at $12.6K in Q4 2023.
313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Cullen/Frost Bankers's 13F filing for Q2 2026, filed 27 Jul 2026.